nach oben

Erschienen in:

01.06.2004 | Original Article

Potential of chemotherapy–herb interactions in adult cancer patients

verfasst von: Jeannine S. McCune, Amy J. Hatfield, Anne A. R. Blackburn, Patricia O. Leith, Robert B. Livingston, Georgiana K. Ellis

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

The purpose of this study was to examine the specific herbs or vitamins (HV) used by patients receiving chemotherapy. Specifically, the following aspects were investigated: (1) HV use among adult cancer patients receiving chemotherapy, (2) the frequency of potential chemotherapy–HV interactions, (3) communication patterns between oncologists and their cancer patients taking HV, and (4) patients’ reactions to two hypothetical scenarios of chemotherapy–HV interactions.

Patients and methods

Adult cancer patients receiving chemotherapy at a university-based outpatient clinic over a 1-month period were sent a validated eight-page questionnaire regarding the use of complementary/alternative medicine, focusing on HV use. A total of 76 patients participated; relevant medical information was obtained from study participants’ charts. The chemotherapy received was compared with HV use to assess for potentially detrimental chemotherapy–HV interactions.

Results

HV use in patients receiving chemotherapy was common (78%), with 27% of the study participants being at risk of a detrimental chemotherapy–HV interaction. Most patients (>85%) would discontinue their HV or ask their medical oncologist for advice if a detrimental chemotherapy–HV interaction was suspected. Although most patients discussed HV use with their oncologist, the majority also relied on their friends and naturopathic physician for information regarding HV.

Conclusions

Considerable potential exists for detrimental chemotherapy–HV interactions. Methods to improve communication of HV use between cancer patients receiving chemotherapy and health-care practitioners are necessary to identify and minimize the risk of these interactions.

Astin JA (1998) Why patients use alternative medicine: results of a national study. JAMA 279:1548–1553PubMed

Bailey DG, Malcolm J, Arnold O, Spence JD (1998) Grapefruit juice–drug interactions. Br J Clin Pharmacol 46:101–110PubMed

Bernstein BJ, Grasso T (2001) Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Huntingt) 15:1267–1272; discussion 1272–1268, 1283

Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D, Nelson PS (2002) Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst 94:1641–1647CrossRefPubMed

Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18:2515–2521PubMed

Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739PubMed

De Lemos M (2002) Safety issues of soy phytoestrogens in breast cancer patients. J Clin Oncol 20:3040–3041; author reply 3041–3042PubMed

Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328:246–252PubMed

Eisenberg D, Davis R, Ettner S, Appel S, Wilkey S, Rompay M, Kessler R (1998) Trends in alternative medicine use in the United States, 1990–1997. JAMA 280:1569–1575PubMed

10.

Fernandez CV, Stutzer CA, MacWilliam L, Fryer C (1998) Alternative and complementary therapy use in pediatric oncology patients in British Columbia: prevalence and reasons for use and nonuse. J Clin Oncol 16:1279–1286PubMed

11.

Fugh-Berman A (2000) Herb-drug interactions [published erratum appears in Lancet 2000 Mar 18;355(9208):1020]. Lancet 355:134–138PubMed

12.

Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94:39–49CrossRefPubMed

13.

Kemper KJ, Amata-Kynvi A, Sanghavi D, Whelan JS, Dvorkin L, Woolf A, Samuels RC, Hibberd P (2002) Randomized trial of an internet curriculum on herbs and other dietary supplements for health care professionals. Acad Med 77:882–889PubMed

14.

Kemper KJ, Amata-Kynvi A, Dvorkin L, Whelan JS, Woolf A, Samuels RC, Hibberd P (2003) Herbs and other dietary supplements: healthcare professionals’ knowledge, attitudes, and practices. Altern Ther Health Med 9:42–49

15.

Labriola D, Livingston R (1999) Possible interactions between dietary antioxidants and chemotherapy. Oncology (Huntingt) 13:1003–1008; discussion 1008, 1011–1002

16.

Lamson DW, Brignall MS (1999) Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 4:304–329PubMed

17.

Lamson DW, Brignall MS (2000) Antioxidants and cancer therapy II: quick reference guide. Altern Med Rev 5:152–163PubMed

18.

Litwin M (1995) How to measure survey reliability and validity, 1st edn. SAGE Publications, Thousand Oaks

19.

Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst 94:1247–1249CrossRefPubMed

20.

McCune JS, Ellis GK, Leith PO, Winter LL, Rendlemen AA, Gillenwater HH, Livingston RB (2001) Use of herbal and vitamin therapies (HV) in adult cancer patients: assessment of potential chemotherapy–HV interactions. Proc ASCO 19:408a

21.

Mills E (2003) Health food store recommendations: implications for breast cancer patients. Breast Cancer Res 5:R170–174CrossRefPubMed

22.

Morant R, Senn E, Bolliger B, Dupont V, Florio I, Fuerstenberger G, Glaus A, Richter R, Senn H (2003) St. John’s Wort extract relieves hot flashes in women with breast cancer—preliminary results of a phase II study. In: 2003 ASCO Annual Meeting Proceedings. ASCO, Chicago, IL, p 3178

23.

Morris KT, Johnson N, Homer L, Walts D (2000) A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179:407–411CrossRefPubMed

24.

Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM (2000) Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage 20:374–387CrossRefPubMed

25.

Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ (2003) Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103:323–328CrossRefPubMed

26.

Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St John’s wort. Lancet 355:547–548PubMed

27.

Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J (2002) The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34:234–238CrossRefPubMed

28.

Reif S, Nicolson MC, Bisset D, Reid M, Kloft C, Jaehde U, McLeod HL (2002) Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 58:491–494CrossRefPubMed

29.

Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR (1994) O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4 [published erratum appears in Mol Pharmacol 1995 Sep;48(3):568]. Mol Pharmacol 45:352–358PubMed

30.

Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed

31.

Risberg T, Lund E, Wist E (1995) Use of non-proven therapies. Differences in attitudes between Norwegian patients with non-malignant disease and patients suffering from cancer. Acta Oncol 34:893–898PubMed

32.

Schofield PE, Juraskova I, Butow PN (2003) How oncologists discuss complementary therapy use with their patients: an audio-tape audit. Support Care Cancer 11:348–355PubMed

33.

Sun LZ, Currier NL, Miller SC (1999) The American coneflower: a prophylactic role involving nonspecific immunity. J Altern Complement Med 5:437–446PubMed

34.

Swisher EM, Cohn DE, Goff BA, Parham J, Herzog TJ, Rader JS, Mutch DG (2002) Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol 84:363–367CrossRefPubMed

35.

Walker JB (2002) Evaluation of the ability of seven herbal resources to answer questions about herbal products asked in drug information centers. Pharmacotherapy 22:1611–1615PubMed

36.

Warrick PD, Irish JC, Morningstar M, Gilbert R, Brown D, Gullane P (1999) Use of alternative medicine among patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 125:573–579PubMed

37.

Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenberg DM (2002) Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 137:889–903PubMed

38.

West BH, Taylor JD, Griesback EN, Taylor LT (eds) (1982) Prentice-Hall encyclopedia of mathematics. Prentice-Hall, Englewood Cliffs, NJ, pp 385–391

39.

Wyatt GK, Friedman LL, Given CW, Given BA, Beckrow KC (1999) Complementary therapy use among older cancer patients. Cancer Pract 7:136–144CrossRefPubMed

Titel: Potential of chemotherapy–herb interactions in adult cancer patients
verfasst von: Jeannine S. McCune
Amy J. Hatfield
Anne A. R. Blackburn
Patricia O. Leith
Robert B. Livingston
Georgiana K. Ellis
Publikationsdatum: 01.06.2004
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 6/2004
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-004-0598-1

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Potential of chemotherapy–herb interactions in adult cancer patients